Annual General Meeting brought forward to March 30 2015

The Board of NeuroVive Pharmaceutical AB (publ) has decided to bring forward the
Annual General Meeting 2015 to Monday 30 March, 2015, at 4 p.m. at Medicon
Village, Scheelevägen 2, in Lund, Sweden to be able to focus on matters
connected with the CIRCUS-study during the latter part of spring.
Shareholders are entitled to have a matter addressed by the Annual General
Meeting as long as their request has been received by the Board of Directors by
9 February 2015. The Board of Directors can be contacted by email at:
styrelsen@neurovive.com, or by mail at: NeuroVive Pharmaceutical AB, FAO: Greg
Batcheller, Medicon Village, 223 81 Lund, Sweden.

Shareholders wishing to propose members of the Nomination Committee can contact
the Committee by email at: valberedningen@neurovive.com, or by mail at:
NeuroVive Pharmaceutical AB, FAO: Nomination Committee, Medicon Village, 223 81
Lund, Sweden. In order for the Nomination Committee to consider the proposals
received with due care, proposals must be received by the Nomination Committee
by no later than 2 February 2015.

About NeuroVive Pharmaceutical

NeuroVive Pharmaceutical AB (publ), a leading mitochondrial medicine company, is
developing a portfolio of products to treat acute cardiovascular and
neurological conditions through mitochondrial protection. These medical
conditions are characterized by a pressing medical need and have no approved
pharmaceutical treatment options at present. NeuroVive’s products CicloMulsion®
(heart attack) and NeuroSTAT® (traumatic brain injury) are currently being
evaluated in phase III and phase II studies, respectively. NeuroVive’s research
programs also include products for the treatment of antiviral indications
(Hepatitis B/C), brain cell injury in stroke patients, and drug candidates for
cellular protection and treating mitochondria-related energy regulation
diseases. NeuroVive’s shares are listed on NASDAQ OMX, Stockholm, Sweden.

For Investor Relations and media questions, please contact:
Ingmar Rentzhog, Laika Consulting, Tel: +46 (0)46 275 62 21 or ir@neurovive.se
It is also possible to arrange an interview with NeuroVive’s CEO Mikael
Brönnegård at the above contact.

NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard), Fax: +46 (0)46 888 83 48
info@neurovive.se, www.neurovive.se

NeuroVive Pharmaceutical AB (publ) is required to publish the information in
this news release under The Swedish Securities Market Act. The information was
submitted for publication on 12 January 2015, at 14.00 p.m. CET.
NeuroVive Pharmaceutical AB (publ) - the mitochondrial medicine company. The
company is listed on NASDAQ OMX Stockholm, Small Cap, under the ticker symbol
NVP. The share is also traded on the OTC market in the US. NeuroVive
Pharmaceutical (OTC: NEVPF) trades on the OTC Grey Market. Investors can find
Real-Time quotes and market information for the company
at www.otcmarkets.com/stock/NEVPF/quote (http://htt://www.otcmarkets.com/stock/N
E 
VPF/quot)